MY103952A - Aqueous formulations containing a piperidinylcyclopentyheptenoic acid derivative - Google Patents

Aqueous formulations containing a piperidinylcyclopentyheptenoic acid derivative

Info

Publication number
MY103952A
MY103952A MYPI88001508A MYPI19881508A MY103952A MY 103952 A MY103952 A MY 103952A MY PI88001508 A MYPI88001508 A MY PI88001508A MY PI19881508 A MYPI19881508 A MY PI19881508A MY 103952 A MY103952 A MY 103952A
Authority
MY
Malaysia
Prior art keywords
aqueous formulations
piperidinylcyclopentyheptenoic
acid derivative
formulations containing
preparations
Prior art date
Application number
MYPI88001508A
Other languages
English (en)
Inventor
Finch Harry
John Phillips Anthony
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878729823A external-priority patent/GB8729823D0/en
Priority claimed from GB888804422A external-priority patent/GB8804422D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY103952A publication Critical patent/MY103952A/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI88001508A 1987-12-22 1988-12-22 Aqueous formulations containing a piperidinylcyclopentyheptenoic acid derivative MY103952A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878729823A GB8729823D0 (en) 1987-12-22 1987-12-22 Complexes
GB888804422A GB8804422D0 (en) 1988-02-25 1988-02-25 Complexes

Publications (1)

Publication Number Publication Date
MY103952A true MY103952A (en) 1993-10-30

Family

ID=26293226

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI88001508A MY103952A (en) 1987-12-22 1988-12-22 Aqueous formulations containing a piperidinylcyclopentyheptenoic acid derivative

Country Status (29)

Country Link
JP (1) JPH02210A (es)
KR (1) KR890009402A (es)
CN (1) CN1034132A (es)
AT (1) AT395943B (es)
AU (1) AU615245B2 (es)
BE (1) BE1001704A3 (es)
CA (1) CA1328078C (es)
CH (1) CH676665A5 (es)
DE (1) DE3843059A1 (es)
DK (1) DK712888A (es)
ES (1) ES2011727A6 (es)
FI (1) FI885920A (es)
FR (1) FR2624731B1 (es)
GB (1) GB2211737B (es)
GR (1) GR880100854A (es)
HU (1) HU204700B (es)
IE (1) IE61995B1 (es)
IL (1) IL88764A0 (es)
IT (1) IT1224835B (es)
LU (1) LU87411A1 (es)
MY (1) MY103952A (es)
NL (1) NL8803126A (es)
NO (1) NO885689L (es)
NZ (1) NZ227446A (es)
PH (1) PH24982A (es)
PL (1) PL276595A1 (es)
PT (1) PT89301B (es)
SE (1) SE502288C2 (es)
ZW (1) ZW18088A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814725D0 (en) * 1988-06-21 1988-07-27 Glaxo Group Ltd Medicaments
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
KR100825736B1 (ko) * 2005-12-07 2008-04-29 한국전자통신연구원 무선 xml 전자 서명 서비스 제공 장치 및 그 방법
KR100832740B1 (ko) * 2007-01-17 2008-05-27 한국과학기술원 분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (es) * 1970-06-10 1975-02-04
JPS5443569B2 (es) * 1972-07-05 1979-12-20
HU181703B (en) * 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS57183772A (en) * 1981-04-29 1982-11-12 Glaxo Group Ltd Aminocyclopentanol acids and esters, manufacture and medicinal composition
JPS58116423A (ja) * 1981-12-28 1983-07-11 Sumitomo Chem Co Ltd メタノプロスタサイクリン製剤組成物
JPS58192821A (ja) * 1982-04-30 1983-11-10 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患の治療剤
JPS5946228A (ja) * 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
JPS5973576A (ja) * 1982-09-16 1984-04-25 グラクソ・グル−プ・リミテツド ピペリジニルシクロペンタノ−ルヘプテン酸塩
GB2127406B (en) * 1982-09-16 1986-03-05 Glaxo Group Ltd Piperidinlycyclopentanolheptenoic acid salt
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60150039A (ja) * 1984-01-17 1985-08-07 Minolta Camera Co Ltd 水陸両用固定焦点カメラ
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物

Also Published As

Publication number Publication date
AU2735688A (en) 1989-06-22
NL8803126A (nl) 1989-07-17
IE883820L (en) 1989-06-22
JPH02210A (ja) 1990-01-05
KR890009402A (ko) 1989-08-01
CN1034132A (zh) 1989-07-26
ES2011727A6 (es) 1990-02-01
CH676665A5 (es) 1991-02-28
LU87411A1 (fr) 1989-07-07
CA1328078C (en) 1994-03-29
NZ227446A (en) 1991-08-27
DE3843059A1 (de) 1989-07-13
PH24982A (en) 1990-12-26
IE61995B1 (en) 1994-12-14
GB8829793D0 (en) 1989-02-15
NO885689D0 (no) 1988-12-21
SE502288C2 (sv) 1995-09-25
GB2211737A (en) 1989-07-12
BE1001704A3 (fr) 1990-02-13
FR2624731B1 (fr) 1992-10-23
NO885689L (no) 1989-06-23
IT8848702A0 (it) 1988-12-21
PT89301B (pt) 1995-07-03
GB2211737B (en) 1991-12-11
DK712888D0 (da) 1988-12-21
HU204700B (en) 1992-02-28
IL88764A0 (en) 1989-07-31
PL276595A1 (en) 1989-08-21
SE8804607D0 (sv) 1988-12-21
DK712888A (da) 1989-06-23
ZW18088A1 (en) 1989-07-26
ATA313088A (de) 1992-09-15
GR880100854A (el) 1994-03-31
AT395943B (de) 1993-04-26
FI885920A (fi) 1989-06-23
IT1224835B (it) 1990-10-24
FR2624731A1 (fr) 1989-06-23
PT89301A (pt) 1990-06-29
SE8804607L (sv) 1989-06-23
AU615245B2 (en) 1991-09-26
HUT50040A (en) 1989-12-28

Similar Documents

Publication Publication Date Title
AU588202B2 (en) Dosage form for delivering acid sensitive beneficial agent
AU661018B2 (en) Further novel 5-amino-4-hydroxyhexanoic acid derivatives as therapeutic agents
AU3183389A (en) Human relaxin formulation
MY101791A (en) New benzimidazole derivatives
AU7194691A (en) Therapeutic use of indole-3-yl-carboxylic acid endo-8- methyl-8-aza-bicyclo(3,2,1)oct-3-yl ester
GR3026218T3 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
AU7960287A (en) Prodrug derivatives of carboxylic acid drugs
HK104095A (en) Pharmaceutical formulations of acid labile substrances for oral use
GB2229921B (en) Treatment for hyperparathyroidism with use of vitamin d derivatives
AU2514292A (en) Transdermal formulations for administering prazosin
GR3006091T3 (es)
AU2724588A (en) Gamma interferon formulation
AU2617692A (en) Novel acylals of imidazole-5-carboxylic acid derivatives, process for their preparation and their use
MY103952A (en) Aqueous formulations containing a piperidinylcyclopentyheptenoic acid derivative
ES8707734A1 (es) Procedimiento para la obtencion de cefalosporinas
HU9201358D0 (en) 2-amino-pirimidine-4-carboxamide derivatives, process for their production and for the production of medical preparations containing them as active agents
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
AU2065588A (en) Pharmaceutical preparations for external use
WO1987003590A1 (en) Medicament for the treatment of diseases of the liver
NZ229605A (en) Preparation of 1,4-dihydro-6-fluoro-7-(piperazin-1-yl)-4-oxo-3-quinoline (or naphthyridine) carboxylic acid derivatives
EP0418065A3 (en) Dihydrocaffeic acid derivatives, use thereof for medical treatments and pharmaceutical preparations containing same
IT1210320B (it) Dispersioni stabili di polioli contenenti polivinilcloruro eprocedimento per la loro preparazione
HUT53288A (en) Process for production of medical compositions for animals against endoparasite
GR3002381T3 (en) Use of a carboxylic acid in pharmaceutical preparations intended for topical application
IL85093A0 (en) Pharmaceutical compositions containing retinoids for the treatment of psychotic illnesses